Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 2/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852041 | 0.81 | P2RX7 (0.39) | P2RX7SMN1; SMN2HTT | |
| SCHEMBL10297720 | 0.79 | MAP3K14 (0.38) | MAP3K14P2RX7CXCR4ITGB2ICAM1 | |
| SCHEMBL5054785 | 0.79 | CXCR4 (0.38) | MAP3K14CXCR4ITGB2ICAM1ITGAL | |
| SCHEMBL10101759 | 0.79 | CXCR4 (0.36) | MAP3K14CXCR4ITGB2ICAM1ITGAL | |
| SCHEMBL5051454 | 0.79 | CXCR4 (0.38) | MAP3K14CXCR4ITGB2ICAM1ITGAL | |
| SCHEMBL12993334 | 0.79 | CXCR4 (0.36) | MAP3K14CXCR4ITGB2ICAM1ITGAL | |
| SCHEMBL12891532 | 0.79 | MAP3K14 (0.38) | MAP3K14P2RX7CXCR4ITGB2ICAM1 | |
| SCHEMBL12891533 | 0.79 | MAP3K14 (0.38) | MAP3K14P2RX7CXCR4ITGB2ICAM1 | |
| SCHEMBL31482094 | 0.79 | CXCR4 (0.38) | MAP3K14CXCR4ITGB2ICAM1ITGAL | |
| SCHEMBL30630753 | 0.79 | CXCR4 (0.38) | MAP3K14CXCR4ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | claimed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| US-20100168195-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168195-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| WO-2010033495-A2 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | MAP3K14 2681/4885P2RX7 227/4885CXCR4 584/4885 |
| US-20100168195-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | MAP3K14 1931/4885P2RX7 213/4885CXCR4 150/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | MAP3K14 3907/4885P2RX7 445/4885CXCR4 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.